STAT

SEPTEMBER 1, 2023

In the midst of the Covid-19 surge during the winter of 2021, the Pittsburgh-based UPMC health system received 450 doses of Evusheld — a scarce antibody cocktail being used at the time to prevent immunocompromised patients from being infected by the coronavirus. But those doses were just a fraction of a percent of what the sprawling 35-hospital system needed to protect its 200,000 immunocompromised patients.

Hospitals 328

Hospitals 328

PharmaVoice

SEPTEMBER 1, 2023

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

265

265

STAT

SEPTEMBER 1, 2023

The U.S. is running low on primary care physicians, with an estimated shortage of between 17,800 and 48,000 predicted by 2034. The dearth of doctors in this area has broad ramifications, ranging from more patients seeking care from specialty and emergency medicine to increased costs to the health care system  and poorer public health outcomes. One of the challenges to growing the ranks of primary care doctors is that family physicians and others in primary care typically have a much lower i

323

323

PharmaVoice

SEPTEMBER 1, 2023

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

233

233

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 1, 2023

Eleven years ago, the Affordable Care Act codified a critical aspect of postpartum care: breastfeeding support. The hard part — the legislation — was done. Yet so far, no meaningful implementation and enforcement of this policy has occurred.

261

261

ALiEM - Pharm Pearls

SEPTEMBER 1, 2023

A 65-year-old male presented with chest and abdominal pain for three weeks. He endorsed a poor appetite and a weight loss of 16 kilograms in the last month. He denied fever, vomiting, diarrhea, and tarry stools and described having his usual bowel movements. Additional Images Physical Exam Vitals : BP 172/71; HR 127; T 35.9°C; O2 Sat 100% General : In acute distress Cardiovascular : Regular rate and rhythm; no murmur; bilateral upper extremity and lower extremity pulses palpable Gastrointestin

Diabetes 158

Diabetes Hospitals 158

The Pharmacist

SEPTEMBER 1, 2023

Pharmacists working as online prescribers should beware the ‘red flag’ of a patient refusing to allow them to contact their GP, the Pharmacists’ Defence Association (PDA) has warned. It has issued guidance to pharmacist prescribers working in online settings to minimise risk both to themselves and to their patients. And it urged the General Pharmaceutical […] The post Online pharmacies warned over risks of not contacting GPs appeared first on The Pharmacist.

Online Pharmacies 128

Online Pharmacies 128

STAT

SEPTEMBER 1, 2023

After months of legal sparring, Amgen and Horizon Therapeutics settled a lawsuit with the Federal Trade Commission that will allow the company to proceed with their planned $28 billion merger. The agreement comes after the agency challenged the deal over concerns the combined company could abuse its power to entrench the monopolies for two drugs currently sold by Horizon.

Packaging 248

Packaging Drug Pricing 248

Pharma Times

SEPTEMBER 1, 2023

The AI platform and expertise will be combined to discover novel targets for haematological cancers - News - PharmaTimes

147

147

STAT

SEPTEMBER 1, 2023

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Please note that our regular feature — in which we spotlight someone — will return later this month.

197

197

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma Times

SEPTEMBER 1, 2023

Partnership will discover and develop novel antibodies for a range of autoimmune diseases - News - PharmaTimes

145

145

The Thyroid Pharmacist

SEPTEMBER 1, 2023

A few years ago, I visited with family in Poland. At that time, one of my cousins was attending dental school in the European Union. She asked me, “Izabella, is it true that the U.S. government adds fluoride to their water supply, in an effort to reduce dental cavities, instead of educating the public about the effect of sugar consumption and nutrition on health?

Adverse Reactions 115

Adverse Reactions Compounding Chemotherapy Labelling 115

Drug Patent Watch

SEPTEMBER 1, 2023

Annual Drug Patent Expirations for SPY+AGENT+GREEN+KIT Spy Agent Green Kit is a drug marketed by Novadaq Tech and is included in one NDA. It is available from one supplier. There… The post New patent for Novadaq Tech drug SPY AGENT GREEN KIT appeared first on DrugPatentWatch - Make Better Decisions.

105

105

BioPharma Dive

SEPTEMBER 1, 2023

The Swiss pharma said, without details, that it observed “unprecedented” results that could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.

105

105

pharmaphorum

SEPTEMBER 1, 2023

Or Shaval, CEO of Remepy and Shahar Shelly, the company’s chief medical officer, join Editor in Chief Jonah Comstock to talk about their unorthodox approach and the science that underpins it. They discuss how their in-development products are similar and different from traditional digital therapeutics.

99

99

BioPharma Dive

SEPTEMBER 1, 2023

The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.

109

109

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

105

105

European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. Global mRNA-based oncology therapy market At present, the pharmaceutical industry is still awaiting the first regulatory approval of an mRNA-based oncology therapy. mRNA stability and delivery specificity are two of the main obstacles hindering pr

Immunity 92

Immunity Immunization Vaccines 92

Pharmaceutical Technology

SEPTEMBER 1, 2023

Otsuka Pharmaceutical has signed a definitive arrangement agreement to acquire Mindset Pharma, in an all-cash deal worth C$80m ($59.1m).

105

105

European Pharmaceutical Review

SEPTEMBER 1, 2023

Roche’s Alecensa ® (alectinib) is the first anaplastic lymphoma kinase (ALK) inhibitor to demonstrate a reduction in the risk of disease recurrence or death for patients with early-stage ALK-positive non-small cell lung cancer (NSCLC) in a Phase III trial. The Phase III ALINA study compared Alecensa to platinum-based chemotherapy. Results from the trial “provide evidence for the first time that this medicine could also play a pivotal role in early-stage disease where there is significant u

Chemotherapy 75

Chemotherapy 75

Pharmaceutical Technology

SEPTEMBER 1, 2023

As per GlobalData, AbbVie has remained the Crohn’s disease market leader over the last five years, with Humira sales of $2.7bn in 2022 in 8MM.

98

98

pharmaphorum

SEPTEMBER 1, 2023

Harnessing CRM to drive innovation, strong customer experiences in life sciences Mike.

108

108

The Guardian - Pharmaceutical Industry

SEPTEMBER 1, 2023

V&A has faced criticism for being slow to disassociate itself from benefactors with role in US opioid epidemic The V&A Dundee has become the latest UK museum to remove a reference to the money it received from the Sackler family amid continuing anger over its central role in the opioid epidemic in the US. The £80m museum, Scotland’s first devoted to design, opened in 2018 and had among its donors the Sackler Trust, which gave £500,000.

70

70

World Pharma News

SEPTEMBER 1, 2023

Cholesterol-lowering statins might protect patients with ulcerative colitis from developing and dying from colorectal cancer. Statin treatment was also associated with a lower risk of death regardless of cause in patients with ulcerative colitis or Crohn's disease. This is according to a study by researchers at Karolinska Institutet in Sweden published in eClinicalMedicine.

68

68

Drug Patent Watch

SEPTEMBER 1, 2023

Annual Drug Patent Expirations for NUMBRINO Numbrino is a drug marketed by Cody Labs Inc and is included in one NDA. It is available from one supplier. The generic ingredient… The post New patent for Cody Labs drug NUMBRINO appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmafile

SEPTEMBER 1, 2023

The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients over the age of six years and for moderate-to-severe binge-eating disorder (BED) in adult patients. Dosing details for the generics remain consistent with Vyvanse, […] The post FDA approves new ADHD and BED generics appeared first on Pharmafile.

Generic Medicine 58

Generic Medicine 58

Drug Patent Watch

SEPTEMBER 1, 2023

Annual Drug Patent Expirations for REZZAYO Rezzayo is a drug marketed by Cidara Theraps and is included in one NDA. It is available from one supplier. There are five patents… The post New patent for Cidara Theraps drug REZZAYO appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmafile

SEPTEMBER 1, 2023

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), met its primary endpoint of disease-free survival (DFS). The drug demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in patients […] The post Genentech shares phase 3 results for ALK-positive early-stage l

Chemotherapy 58

Chemotherapy 58

BioPharma Dive

SEPTEMBER 1, 2023

The newly posted documents show the agency had concerns about the side effects experienced by people with clinical depression who took Sage’s drug, Zurzuvae.

Documentation 59

Documentation 59

pharmaphorum

SEPTEMBER 1, 2023

AI specialist Intelligent Omics bags J&J deal Phil.

100

100

Pharma Mirror

SEPTEMBER 1, 2023

San Antonio’s online suboxone clinics serve as lifesavers for individuals fighting opioid addiction. Offering advanced treatments and personalized care, these online clinics light the dark tunnel of addiction recovery. This post delves into how these clinics aid in patients’ transformative journeys. Understanding the Role of Suboxone in Opioid Addiction Treatment Suboxone is a potent weapon in our arsenal against opioid addiction, primarily utilized in Medication-Assisted Treatment (

52

52

pharmaphorum

SEPTEMBER 1, 2023

Otsuka makes psychedelics play, buying Mindset Phil.

99

99

Pharma Mirror

SEPTEMBER 1, 2023

The integration of artificial intelligence (AI) tools across medical communications is proving to be a transformative development, ushering in increased efficiencies and innovation across the healthcare industry. by Matt Lewis, Global Chief Artificial and Augmented Intelligence Officer at Inizio Medical, an Inizio company A subset of AI, augmented intelligence, refers to the synergy between AI, machine learning, and natural language processing (NLP) technologies to complement human intelligence

Communication 52

Communication 52

pharmaphorum

SEPTEMBER 1, 2023

Sanofi names VC leader Houman Ashrafian as R&D chief Phil.

96

96

Pharma Mirror

SEPTEMBER 1, 2023

North Charleston, SC: Pharmaceutical sterilization and cleaning equipment manufacturer Belimed Life Science, North Charleston, SC, has unveiled custom wash rack design and manufacturing services. A key option offered with the company’s automated cleaning and disinfecting wash systems, the custom wash rack services were developed to help pharmaceutical and nutritional product manufacturers ensure complete cleaning and disinfection of laboratory glassware, tableting tools, containers, valves

52

52